AbbVie is ending an eleven-year agreement with Alphabet’s Calico Labs, according to an internal email obtained by Stat News.

Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers. | Third ...

Mersana Therapeutics' decision earlier this year to go all-in on its antibody-drug conjugate Emi-Le appears to have paid ...

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, ...

After dropping so-so early-stage results on its dual GLP-1/GLP-2 agonist earlier this year, fierce competition in the obesity ...

Century Therapeutics, Candel Therapeutics and MacroGenics have all used their third-quarter earnings releases to disclose how ...

Sanara MedTech dropped its Tissue Health Plus (THP) platform as part of an overall corporate realignment that focuses ...

In 2022, the WHO hailed Novartis’ GanLum as the most promising non-artemisinin-based combination. The Swiss drugmaker ...

Korro Bio delivered a double whammy of bad news, reporting lackluster data on its lead candidate and a pause to its partnership with Novo Nordisk. The biotech, which suffered a 79% stock drop in the ...

In a highly anticipated article, FDA officials Vinay Prasad, M.D., and Martin Makary, M.D., outlined a novel regulatory ...

Grail saw a sharp rise in third-quarter sales as it outlined a firmer FDA submission date for its Galleri cancer blood test. | Grail saw a sharp rise in third-quarter sales as it outlined a firmer FDA ...

After forming from a merger hashed out over plates of tacos about a year ago, nChroma Bio is laying off staff and ...